Ligand conjugated antisense oligonucleotide for the treatment of transthyretin amyloidosis: preclinical and phase 1 data

Authors: Nicholas J. Viney, Shuling Guo, Li‐Jung Tai, Brenda F. Baker, Mariam Aghajan, Shiangtung W. Jung, Rosie Z. Yu, Sheri Booten, Heather Murray, Todd Machemer, Sebastien Burel, Sue Murray, Gustavo Buchele, Sotirios Tsimikas, Eugene Schneider, Richard S. Geary, Merrill D. Benson, Brett P. Monia

Source: ESC Heart Failure, Vol 8, Iss 1, Pp 652-661 (2021)

Subject Terms: Transthyretin, Amyloidosis, Cardiomyopathy, Polyneuropathy, Antisense, Ligand‐conjugated, Diseases of the circulatory (Cardiovascular) system, RC666-701

File Description: electronic resource

Relation: https://doaj.org/toc/2055-5822

Access URL: https://doaj.org/article/3297462a8e6e4c1081fbb6040b37c72e

Potent reduction of plasma lipoprotein (a) with an antisense oligonucleotide in human subjects does not affect ex vivo fibrinolysis

Authors: Michael B. Boffa, Tanya T. Marar, Calvin Yeang, Nicholas J. Viney, Shuting Xia, Joseph L. Witztum, Marlys L. Koschinsky, Sotirios Tsimikas

Source: Journal of Lipid Research, Vol 60, Iss 12, Pp 2082-2089 (2019)

Subject Terms: apolipoprotein(a), thrombosis, atherosclerotic cardiovascular disease, Biochemistry, QD415-436

File Description: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S0022227520310464; https://doaj.org/toc/0022-2275

Access URL: https://doaj.org/article/28dfa1e214734075affad1972af7235c